Axonics, Inc.
9
2
3
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
11.1%
1 terminated/withdrawn out of 9 trials
75.0%
-11.5% vs industry average
0%
0 trials in Phase 3/4
67%
2 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Axonics R20 Post-Market Clinical Follow-up (PMCF) Study for the Indication of Fecal Incontinence
Role: lead
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
Role: lead
Aquarius Pilot Study to Evaluate the New Axonics Trial System
Role: lead
F15 Recharge Free Axonics SNM System Clinical Study
Role: lead
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Role: lead
Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt
Role: lead
Axonics SacRal NeuromodulaTIon System RegisTRY Study
Role: lead
Cycling Study With the Axonics System
Role: lead
Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System (RELAX-OAB)
Role: lead
All 9 trials loaded